Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens

AIDS

Volumn 24, Issue 9, 2010, Pages 1291-1298

  Tungsiripat, Marisa ^a   Bejjani, Dalia El ^b,c   Rizk, Nesrine ^c   O'Riordan, Mary Ann ^c   Ross, Allison C ^c   Hileman, Corrilynn ^c   Storer, Norma ^c   Harrill, Danielle ^c   McComsey, Grace A ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MetroHealth Medical Center   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antiretroviral therapy; Lipoatrophy; Thiazolidenediaones

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIMB; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PPAR GAMMA; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLIDINEDIONES; THYMIDINE;

EID: 77952952324     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328339e274     Document Type: Article

References (23)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well being among HIV-infected homosexual men. AIDS 2001; 15:812-813.
3. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavirsubstitution for nucleoside analogsinpatients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
4. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
5. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
6. Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, Hoy J, et al. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 2008; 198:1794-1803.
7. Viengchareun S, Caron M, Auclair M, Kim MJ, Frachon P, Capeau J, et al. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 2007; 12:919-929.
8. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
9. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, Vidal S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochon-drial function in HIV-infected patients. Antivir Ther 2007; 12:407-415.
10. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
11. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
12. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274.
13. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoa-trophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
14. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007; 195:1754-1761.
15. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004; 140: 786-794.
16. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007; 21:47-57.
17. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Bou-tekatjirt A, et al. Effect of pioglitazone on HIV-1-related lipo-dystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008; 13:67-76.
18. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8:199-207.
19. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143:337-346.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
21. Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17:770-772.
22. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008; 9:254-268.
23. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263-270.